Should a 75-Year-Old Man Be Treated for Prostate Cancer?

Whether a 75-year-old man should be treated for prostate cancer depends far more on his overall health and the aggressiveness of his tumor than on the number 75 itself. A healthy 75-year-old with high-risk disease may benefit enormously from treatment, while a 75-year-old with multiple chronic conditions and a slow-growing tumor may be harmed by it. The real question is not “how old is he?” but “how likely is this cancer to threaten his life before something else does?” Getting that answer right requires looking at comorbidity, tumor risk category, and individual priorities in a way that most people never hear discussed at their first urology appointment.

Why Age Alone Is the Wrong Starting Point

Prostate cancer is unusual among cancers because many men who have it will never die from it. In a large U.S. population-based study, men aged 75 and older with low-risk prostate cancer had only about a 3% chance of dying from that cancer within 10 years, while their chance of dying from something else entirely was far higher, reaching 71% for those with three or more other health conditions.¹ That asymmetry is the core of the decision. Treating a cancer that was never going to cause symptoms means exposing someone to the side effects of surgery, radiation, or hormone therapy for no survival benefit.

But the picture flips for aggressive disease. In that same study, men with high-risk prostate cancer had about an 18% chance of dying from it regardless of how many other health problems they had. The cancer-specific death rate stayed roughly the same across comorbidity groups, while other-cause mortality climbed steeply with age and illness burden. This means the decision is really a race between two risks: will the cancer get him first, or will heart disease, diabetes, lung problems, or another condition? The answer varies dramatically from one 75-year-old to the next.

How Doctors Assess Health Status Instead of Age

The International Society of Geriatric Oncology developed a classification system that sorts older men into groups based on functional health rather than birthday. “Healthy” older patients with controlled chronic conditions and full independence in daily activities should receive the same treatment as younger men. “Vulnerable” patients with reversible impairments can receive standard treatment after those issues are addressed. “Frail” patients with irreversible impairments get adapted, less aggressive treatment. And those who are terminally ill from another condition receive only symptom management.²

This framework reflects a growing recognition that a fit 78-year-old who still plays golf and manages his own household has a fundamentally different outlook than a 72-year-old with poorly controlled heart failure, diabetes, and limited mobility. Chronological age is a rough proxy for life expectancy, but it is often a misleading one. Most major medical organizations agree that the key threshold is whether a man has at least a 10-year life expectancy, since prostate cancer, even aggressive forms, tends to move slowly enough that treatment benefits take years to materialize.

What Screening Guidelines Say About Older Men

The U.S. Preventive Services Task Force recommends against routine PSA-based screening for prostate cancer in men 70 and older.³ This recommendation sometimes causes confusion: it does not mean prostate cancer should go untreated if discovered. It means that for men in this age group, the harms of screening, including biopsies, overdiagnosis of cancers that would never cause trouble, and anxiety, generally outweigh the benefits across the population. Most major organizations, including the American Cancer Society and the American Urological Association, recommend that screening decisions be individualized based on life expectancy and patient preferences rather than applied rigidly by age cutoff.

If a man already has a diagnosis, the screening question is behind him. The question becomes what to do next, and that is where risk stratification and health assessment take over.

Low-Risk and Intermediate-Risk Disease in Older Men

For low-risk prostate cancer, the evidence is clear: aggressive treatment at 75 is almost always unnecessary. In population data, cancer-specific mortality for low-risk disease was not significantly affected by age or comorbidity.⁴ The cancer progresses so slowly that other causes of death overtake it. Active monitoring, not aggressive intervention, is the standard approach.

Intermediate-risk disease occupies a gray zone. Cancer-specific mortality is higher than in low-risk disease (around 7% at 10 years in one large cohort) but still modest. A modeling study comparing active surveillance to watchful waiting found that active surveillance yielded more life years and lower rates of cancer death and metastasis across all groups, but the quality-of-life advantage narrowed or disappeared in men diagnosed after 65, particularly when treatment complications persisted long-term.⁵ For a 75-year-old with favorable intermediate-risk disease and several comorbidities, watchful waiting, which monitors symptoms rather than tumor markers and avoids treatment unless symptoms arise, is often the better path.

A concerning trend, however, is that definitive treatment for intermediate-risk disease in men with less than 10 years of life expectancy has actually increased over the past two decades, rising from under 40% to about 60%.⁶ While overtreatment of low-risk disease has declined, it appears some of that intensity has shifted to intermediate-risk cases where the benefit remains uncertain.

High-Risk Disease Changes the Calculus

High-risk prostate cancer is the scenario where age-based reluctance to treat can genuinely cost lives. Data from a national Swedish registry showed that increased curative treatment in men 70 and older with high-risk disease was associated with decreased cancer-specific and overall mortality.⁷ A separate European study found that only about 10% of men aged 75 to 80 with no other health conditions received radical treatment, despite having roughly a 52% probability of surviving at least 10 more years.⁸ Those men were being undertreated based on their age alone.

PSA doubling time, which measures how fast the tumor marker is rising, adds another layer of prediction. In men with advanced disease, a doubling time under nine months made prostate cancer the dominant cause of death across all age and comorbidity groups. When the doubling time was nine months or longer, the cancer and other causes competed more evenly, except in men over 80 with severe comorbidity, where other-cause death dominated.⁹ The speed of the cancer matters as much as its presence.

Surgery After 75

Robot-assisted radical prostatectomy in men 75 and older has been studied at several high-volume centers, and the results are more reassuring than many patients expect. Cancer control was comparable to younger men: positive surgical margin rates, PSA recurrence, and metastasis-free survival showed no significant differences.¹⁰ Urinary continence recovery at 12 months was similar between age groups, with roughly 85-90% of older men regaining functional continence.¹¹

The major difference was erectile function. Only about 27% of men 75 and older recovered erections by three years, compared to 56% of younger men.¹¹ This is a significant quality-of-life trade-off, though its importance varies enormously between individuals. These results come from highly selected patients at experienced centers, so they represent the best-case scenario. A less fit patient at a lower-volume hospital would face higher complication risks.

Radiation Therapy in Older Men

Radiation is the more common treatment path for older men, and the evidence supports its safety in this age group. In a subgroup analysis of a large randomized trial, men 75 and older showed no difference in cancer control or serious side effects compared to younger patients. Five-year biochemical failure-free rates ranged from roughly 85% to 91% depending on the dose schedule, and severe bladder and bowel toxicity remained low, affecting only around 2% and 7-8% respectively.¹²

A Japanese study focusing specifically on men 75 and older treated with radiation found seven-year overall survival around 80% and recurrence-free rates near 89%, with very low rates of severe late toxicity.¹³ Older research using three-dimensional conformal radiation actually found that older patients had better biochemical disease-free survival than younger patients, possibly because their tumors tended to be less aggressive at baseline.¹⁴

Hypofractionated schedules, which deliver fewer but larger doses of radiation, have proven equally effective and are particularly convenient for older patients since they reduce the number of hospital visits. Among men treated with definitive therapy who had limited life expectancy, radiotherapy was by far the most common modality, accounting for about 78-85% of treatments.⁶

The Hidden Costs of Hormone Therapy

Androgen deprivation therapy, which suppresses testosterone, is frequently used in combination with radiation for higher-risk disease and as the primary treatment for advanced prostate cancer. For older men, its side effects deserve special attention because they compound vulnerabilities that already increase with age.

A large meta-analysis found that men on ADT had a 39% higher risk of bone fractures, a 21% higher risk of developing diabetes, and elevated risks of dementia, coronary heart disease, and heart attack compared to prostate cancer patients not on ADT.¹⁵ Another review confirmed a 23% increased fracture risk and a 17% increase in cardiovascular death.¹⁶ Beyond these systemic risks, ADT causes fatigue, loss of muscle mass, weight gain, depression, and cognitive decline.¹⁷

For a 75-year-old man who already faces age-related bone thinning, cardiovascular risk, and perhaps early cognitive changes, adding ADT can meaningfully worsen his functional independence and quality of life. When ADT is used for time-limited courses alongside radiation for localized disease, the trade-off may be acceptable. When it is used indefinitely for advanced disease, the cumulative burden becomes a central part of the treatment equation. The fracture and diabetes risks increase steadily with cumulative doses, meaning longer treatment carries proportionally higher risks.

Quality of Life After Treatment

Each treatment leaves a distinct footprint on daily life. The ProtecT trial, which tracked men for six years after treatment, found that surgery caused immediate and lasting erectile dysfunction in the vast majority of patients (95% shortly after, still 85% at six years) and urinary leakage requiring pads in about a third of men initially, settling to roughly one in five at six years. Radiation caused less incontinence but more bowel problems, including bloody stools and fecal incontinence at six-year follow-up. Men on active monitoring experienced gradual age-related declines in sexual and urinary function without the sharp treatment-related drops.¹⁸

An interesting pattern emerges with age: older men actually report smaller declines in bothersomeness from sexual and urinary side effects, likely because baseline function was already lower and expectations differ. A multi-center study found that at two years, fewer men over 70 reported being bothered by sexual changes compared to men under 60.¹⁹ This does not mean the side effects are trivial. It does mean that the subjective impact of treatment varies as much as the medical impact, and a man’s own priorities should drive the decision.

Focal Therapy as a Middle Path

For older men who have clinically significant cancer but want to avoid the full side-effect profile of surgery or whole-gland radiation, focal ablation therapies are an emerging option. These techniques treat only the part of the prostate where the cancer sits, aiming to destroy the tumor while preserving surrounding tissue and function. A 15-year multi-center experience evaluating focal therapy specifically in men over 70 reported that it offered a viable alternative to radical treatment with lower morbidity.²⁰ Focal therapy is not yet standard of care for all situations and requires careful patient selection, but it fills a gap for men who feel that watchful waiting is too passive and radical treatment is too aggressive.

Genomic Testing and Risk Refinement

One reason the “should he be treated?” question has gotten more nuanced in recent years is the availability of genomic tests that go beyond the traditional measures of stage, grade, and PSA level. RNA expression tests can now help determine whether a tumor classified as intermediate-risk is actually behaving like a low-risk or high-risk cancer, which can push treatment decisions in either direction.²¹ For a 75-year-old man sitting in the ambiguous intermediate-risk category, a genomic test that reveals low biologic aggressiveness can provide confidence that active surveillance is safe, while a result suggesting hidden aggressiveness can justify treatment that might otherwise be deferred on the basis of age.

Racial Disparities in Treatment of Older Men

The tension between overtreatment and undertreatment plays out unevenly across racial groups. Among men 70 and older with high-risk prostate cancer, Black men had about a 20% higher cancer-specific death rate compared to white men after adjusting for tumor characteristics and demographics. At the same time, the gap in receiving definitive treatment was wider for older men than for younger men: Black men over 70 had roughly 40% lower odds of receiving curative treatment compared to white men of the same age, a larger disparity than among men under 70.²² This suggests that age-based biases in treatment decisions compound existing racial inequities, leading to worse outcomes for a group that already faces higher prostate cancer mortality.

The Financial Dimension

Treatment decisions at 75 also carry financial weight that patients and families rarely discuss openly with doctors. Among men with metastatic prostate cancer, those experiencing high financial strain were far more likely to cut spending on basic necessities and deplete their savings to pay for treatment. In one survey, about 35% of men with high financial toxicity reduced spending on basic goods, and over 60% dipped into savings, compared to much smaller fractions of men with lower financial burden. For a retired man on a fixed income, the long-term costs of hormone therapy, radiation, or repeated monitoring appointments can quietly erode financial stability, especially if treatment continues for years. This makes it all the more important that treatment is likely to provide a genuine survival benefit before it is initiated.

How to Approach the Conversation

Shared decision-making sounds like a buzzword, but in prostate cancer management for older men, it is genuinely the recommended approach. Personalized decision aids that incorporate a man’s comorbidities, tumor characteristics, and personal values have shown that no single treatment option dominates for every patient. With one particular set of preferences, watchful waiting is the best choice; with another, radiation wins; with another, surgery.²³ Decision aids consistently improve patients’ knowledge about their options and increase satisfaction with the ultimate choice, even though they don’t change whether shared decision-making formally happens.²⁴

A practical starting point for any 75-year-old facing this decision is to ask his doctor three questions. First, what is my estimated life expectancy based on my overall health, not just my age? Second, what risk category is my cancer, and how fast is it likely to progress? Third, if we treat it, what is the realistic chance that treatment extends my life versus the realistic chance it only adds side effects? If those answers point toward a man who is likely to live another decade with an aggressive cancer, treatment makes sense. If they point toward a man with limited life expectancy and slow-growing disease, the best “treatment” may be to leave it alone entirely and focus on living well.